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Abstract
Background: Dysregulated expression of microRNAs (miRNAs) has been previously observed in human cancer
tissues and shown promise in defining tumor status. However, there is little information as to if or when
expression changes of miRNAs occur in normal tissues after carcinogen exposure.
Results: To explore the possible time-course changes of miRNA expression induced by a carcinogen, we treated mice
with one dose of 120 mg/kg N-ethyl-N-nitrosourea (ENU), a model genotoxic carcinogen, and vehicle control. The
miRNA expression profiles were assessed in the mouse livers in a time-course design. miRNAs were isolated from the
livers at days 1, 3, 7, 15, 30 and 120 after the treatment and their expression was determined using a miRNA PCR Array.
Principal component analysis of the miRNA expression profiles showed that miRNA expression at post-treatment days
(PTDs) 7 and 15 were different from those at the other time points and the control. The number of differentially
expressed miRNAs (DEMs) changed over time (3, 5, 14, 32, 5 and 5 at PTDs 1, 3, 7, 15, 30 and 120, respectively). The
magnitude of the expression change varied with time with the highest changes at PTDs 7 or 15 for most of the DEMs.
In silico functional analysis of the DEMs at PTDs 7 and 15 indicated that the major functions of these ENU-induced
DEMs were associated with DNA damage, DNA repair, apoptosis and other processes related to carcinogenesis.
Conclusion: Our results showed that many miRNAs changed their expression to respond the exposure of the
genotoxic carcinogen ENU and the number and magnitude of the changes were highest at PTDs 7 to 15. Thus,
one to two weeks after the exposure is the best time for miRNA expression sampling.
Background
MicroRNA (miRNA) is a class of small nucleic acids that
negatively regulate gene expression [1]. They are single-
stranded RNA molecules that are not translated into pro-
teins. Each miRNA molecule is partially complementary
to one or more mRNA transcripts, and functions to
down-regulate gene expression by inhibiting protein
translation or destabilizing target transcripts [2]. The
expression of miRNAs is regulated developmentally and
spatially, and is involved in differentiation and prolifera-
tion of cells [3]. Therefore, miRNA molecules can modu-
late a wide array of growth and differentiation processes
in cancer [4]. A number of studies have demonstrated
that miRNA expression is commonly dysregulated in
human cancer; and that miRNAs are extensively involved
in carcinogenesis and act as either dominant or recessive
cancer genes [5]. miRNA expression profiling has shown
promise in defining tumor malignancy status and is sur-
prisingly informative when used to identify tumor types,
differentiation states and developmental lineages [6].
The available information on miRNA function suggests
that miRNA expression profiles might also have predic-
tive value for assessing chemical carcinogenicity. It has
been reported that expression of some miRNAs is asso-
ciated with tumor initiation [7]. Thus, specific miRNAs
could represent attractive molecules as informative bio-
markers of exposure to carcinogens. Studies on the rela-
tionship between miRNAs and carcinogen exposure have
been previously reported [8] and miRNA expression has
been shown to be dysregulated by many carcinogenic
agents like 4-(methylnitrosamino)-1-(3-pyridyl)-1-buta-
none (NNK) [9], 7,12-dimethylbenz[a]anthrance [10],
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The results of these studies indicate that miRNAs are
involved in early stages of carcinogenesis and suggest
that miRNAs could be a useful tool for detecting carcino-
gen exposure. Expression data from these studies,
however, were generated primarily from chronic or sub-
chronic carcinogen exposures in which the animals were
treated with multiple doses of carcinogens over a long
period such as 20 or 24 weeks [9,11]. This kind of studies
are able to reveal cumulative effects of chemical treat-
ments on miRNA expression. However, they are unable
to provide time course miRNA expression data caused by
a single dose of chemical treatment.
Time-course data is an important component of toxi-
cological studies. It reveals a toxicological response as a
transient, continuous, or delayed response. Since the reg-
ulation of miRNA expression is a dynamic process, a
temporal design provides information regarding an
appropriate sampling time for miRNA expression change
after carcinogen treatment. In this study, N-ethyl-N-
nitrosourea (ENU), a model genotoxic carcinogen, is
used for the carcinogen treatment. We treated mice with
o n ed o s eo fE N Ua n dm e a s u r e dt h ee x p r e s s i o nl e v e lo f
miRNAs in the liver of the treated and control mice at
several posttreatment times. This treatment and sampling
design allowed us to analyze the time-course changes of
miRNA expression in tissues exposed to the carcinogen.
We have previously published the mutant frequency data
from mice treated in this study [13]
ENU is mutagenic in a wide variety of mutagenicity
test systems and carcinogenic in various organs of mam-
mals [14]. It induces hepatocellular carcinomas in
mouse liver that receives a single dose of ENU [15].
Thus, ENU is a suitable genotoxic carcinogen for study-
ing the time course expression of miRNAs. Usually, bio-
logical effects of a carcinogen are affected by various
factors, including chemical absorption, distribution,
metabolism, and elimination. ENU, however, directly
alkylates nucleotides without metabolic activation [14].
Thus, choosing ENU as a model carcinogen avoids the
effects of these unrelated processes to a large extent due
to ENU’s direct activity. Most importantly, abundant
information on the time-course effects of ENU toxicity
and carcinogenicity has been accumulated including
data regarding DNA adducts [16], gene mutations [13],
gene expression [17] and tumor formation [18]. This
information is valuable to understand alteration of
miRNA expression induced by ENU exposure.
Results
Principal component analysis
To globally view the temporal changes of miRNA
expression induced by a single ENU treatment at differ-
ent posttreatment time points, principal component
analysis was performed to classify all of the 35 animal
samples (5 samples each group for post-treatment days
[PTDs] 1, 3, 7 and 15 after ENU treatment; 4 samples
each group for PTDs 30 and 120; and 7 samples for the
control group). The normalized Ct values of 376 miR-
N A s( A d d i t i o n a lF i l e1 )w e r eu s e df o rt h i sa n a l y s i sa n d
the results for the first 3 principal components are
shown in Figure 1. The samples can be roughly divided
into 2 groups. Samples at PTDs 7 and 15 are grouped
together while samples from the other groups including
the control group and treatment groups at PTDs 1, 3,
30 and 120 are clustered together. The results from the
principal component analysis suggest that the miRNA
expression was globally altered by ENU treatment at
PTDs 7 and 15, but not at PTDs 1, 3, 30 and 120
although two samples at PTD 3 also fall into the PTDs
7 and 15 group, which might reflect that some animals
at PTD 3 had miRNA expression patterns similar to
those from samples at PTDs 7 and 15.
Time course analysis of miRNA expression
There were 43 miRNAs whose expression was dysregu-
lated by ENU treatment at least at one posttreatment
time. The names of those differentially expressed miR-
NAs (DEMs), their fold changes against the controls and
the posttreatment time points when their expression was
altered, as well as their possible functions reported in the
literature are listed in Table 1 (see Additional File 2 for
the fold changes and p values of all the miRNAs in the
PCR array). The amount of the DEMs was changed with
time after ENU treatment (Figure 2). Only 3 and 5 DEMs
were found at PTDs 1 and 3, respectively. This amount
increased to 14 and 32 at PTDs 7 and 15, and then
decreased to 5 each at PTDs 30 and 120. Most of the
DEMs (4 out of 6) at PTDs 1 and 3 were also observed at
PTDs 7 and 15. Two miRNAs, mmu-miR-34a and mmu-
miR-34b-5p, were up-regulated at all posttreatment time
points except day 120. Most of the miRNAs that were
d i f f e r e n t i a l l ye x p r e s s e da tb o t hP T D s7a n d1 5h a dt h e
same change directions and similar change magnitudes at
the two time points, indicating miRNA alteration during
this period was relatively stable (Table 1). However,
DEMs at PTD 120 were different from those found in
previous posttreatment time points except for mmu-
miR-453 that was also dysregulated at PTDs 7 and day 15
but with an opposite change direction (Table 1).
Confirmation of the temporal expression changes of
three miR-34 family miRNAs and one miR-762 family
miRNA by individual TaqMan assays
The miR-34 family is worth special attention because
two of its members, mmu-miR-34a and mmu-miR-34b-
5p, were significantly up-regulated one day after ENU
exposure and maintained increased expression at the
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Page 2 of 145s u b s e q u e n tt i m ep o i n t su pt oP T D3 0 ,w h i l ea n o t h e r
family member, mmu-miR-34c, displayed significant
over-expression at multiple time points from PTD 3 to
3 0 .T os e r v ea sac o n f i r m a t i o no ft h ed a t af r o mR T
2-
mouse miRNA PCR Array, a different real-time PCR
platform, TaqMan miRNA assay, was used to measure
the time-course changes of miR-34 family members
induced by the ENU treatment using the same RNA
samples. For TaqMan miRNA assay, all of the samples
were reversely transcribed simultaneously and the PCRs
for the different samples were run in the same plates.
This procedure can greatly reduce the inter-plate varia-
bility that could be produced when PCR arrays are used.
A comparison of miR-34 family miRNA expression mea-
sured by the two different platforms is shown in Figure
3 .T h er e s u l t sf r o mt h et w or e a l - t i m eP C Ra s s a yp l a t -
forms are very consistent and show similar temporal
kinetics of miRNA expression for miR-34 family miR-
NAs, rising from day 1 or 3, reaching peaks at day 15,
and decreasing until the end of observation, day 120.
Another miRNA, mmu-miR-762 that is not similar with
miR-34 family miRNAs in sequence, were also examined
to confirm the array data. The consistency between two
platforms was also observed (Figure 3).
Hierarchical clustering analysis of the DEMs at different
posttreatment times
The 43 DEMs were grouped using hierarchical cluster-
ing methods based on their logarithmically transformed
fold changes. The result is shown in Figure 4. The
DEMs were clustered into four groups. Groups I and II
included the DEMs whose expression was mainly up-
regulated. While the DEMs in Group II were up-regu-
lated across all time points, those in Group I showed
slightly down-regulated in one or two time points.
Groups III and IV composed of DEMs whose expres-
sions were down-regulated. Day 7 and 15 clearly show
the highest fold changes compared to other time points,
indicating miRNA expression reached maximal levels or
changes between the two time points (Figure 4 and 5).
In silico Functional analysis of the DEMs
A literature search of the PubMed database was con-
ducted using the gene name of each DEM without con-
sidering species difference since miRNA functions are
relatively conservative across different species [19].
Twenty seven out of 43 of the DEMs have been func-
tionally investigated by biological experiments (Table 1).
M a n yo ft h e s em i R N A sw e r ed y s r e g u l a t e di nt u m o r so r
Figure 1 Principal component analysis of liver samples collected at different times after ENU treatment. The samples were analyzed
according to the expressions of 376 mouse miRNAs using auto-scale method.
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Page 3 of 14Table 1 MicroRNAs whose expressions were significantly changed by ENU in at least one post-treatment time point
MicroRNA Day 1 Day 3 Day 7 Day 15 Day 30 Day 120 Function
let-7b + Ectopic expression of let-7b reduced HMGA2 expression and cell
proliferation in a lung cancer cell line [33].
miR-106b + miR-106b was up-regulated in several human tumors compared with
adjacent normal tissues and formed a negative-feedback loop with
cell cycle regulator E2F1 [43].
miR-130a + Expression of miR-130a was significantly up-regulated in primary
glioblastomas compared with normal peripheral brain tissue [44].
miR-130b + miR-130b showed increased expression in patients with primary WHO
grade II gliomas that spontaneously progressed to WHO grade IV
secondary glioblastomas [45]. miR-130b was also up-regulated in
human T-cell leukemia virus 1 (HTLV-1)-mediated cellular
transformation [46].
miR-135b + + + + miR-135b expressed was increased in patients with post-surgery
elevation of prostate-specific antigen (chemical relapse), as compared
with patients with non-relapse disease [47].
miR-138 + miR-138 suppresses invasion and promotes apoptosis in head and
neck squamous cell carcinoma cell lines [34].
miR-144 + Introduction of miR-144 affected caspase activation in TRAIL-induced
apoptosis pathway [48].
miR-150 - Control of B cell differentiation by targeting the transcription factor c-
Myb [49].
miR-219 + miR-219 displayed dysregulated expression in human tongue
carcinomas [50].
miR-222 + + miR-222 was up-regulated in atypical teratoid-rhabdoid tumors [51].
miR-301a + miR-301a expression was significantly differentiated in smoker versus
non-smoker [52].
miR-302c* - - - - - - ND
miR-32 + Over-expression of miR-32 was associated with poor outcome of
human kidney cancer [53].
miR-335-5p + + miR-335 was highly expressed in pediatric acute myeloid leukemia
[54].
miR-337-5p + ND
miR-339-5p + ND
miR-34a + + + + + + + + Regulation of p53-mediated apoptosis [32].
miR-34b-5p + + + + + + + + + + + Induction of cell cycle arrest by joining p53 network [55].
miR-34c + + + + + + Induction of cell cycle arrest by joining p53 network [35].
miR-369-5p - - - - - - miR-369-5p was up-regulated in mesenchymal stem cells propagation
[56].
miR-411 - ND
miR-423-5p + + miR-423-5p was involved in muscle development and growth and
showed greatest in the neonate development stage [57].
miR-434-5p - ND
miR-451 + miR-451 expression was up-regulated in multidrug resistant cancer
cell lines [58].
miR-453 - - + A variant affecting miR-453’s putative target site in estrogen receptor
(ESR) 1 is associated with breast cancer risk in premenopausal women
[59].
miR-466d-5p + + ND
miR-484 + miR-484 was involved in adrenal tumorigenesis [60].
miR-487b + ND
miR-590-3p + + + miR-590-3p and other miRNAs were suggested to mediate control of
autoimmune gene expression [61].
miR-590-5p + miR-590 was involved in regulating the expression of transforming
growth factor TGF-beta1 and its receptor TGF-betaRII [62].
miR-672 + + + ND
miR-677 + + ND
miR-700 + ND
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Page 4 of 14tissues exposed to carcinogens. They played roles in cell
proliferation, cell cycle regulation, cellular transforma-
tion, immune response, invasion, apoptosis, tissue devel-
opment and growth. Some of the DEMs are putative
tumor suppressors or oncogenes such as miR-34a (see
literature cited in Table 1).
Although the functions of the DEMs are highly related
to tumorigenesis according to the reports, the studies on
the miRNA functions were conducted in different spe-
cies and various biological systems. To explore the func-
tional relationship between miRNA expression changes
and ENU treatment, we used the top computationally-
predicted target genes of these DEMs according to the
sequence complementarity between miRNA and their
target mRNAs for our functional analysis. Such
approaches have been widely used for functional analysis
of miRNA target genes since miRNAs exert their gene
regulatory activity primarily by base pairing to the 3’
UTR of their target mRNA, leading to mRNA degrada-
tion or translational inhibition [20]. Thirty six DEMs at
PTDs 7 and 15 were used for this analysis because the
principal component analysis showed that the global
miRNA expression was altered by ENU treatment at
these two time points. The selected target genes of the
Table 1 MicroRNAs whose expressions were significantly changed by ENU in at least one post-treatment time point
(Continued)
miR-707 + ND
miR-762 + miR-762 was up-regulated in tumor tissue induced by DMBA [10].
miR-871 - ND
miR-875-3p - - - ND
miR-877 + ND
miR-883a-5p - ND
miR-93 + miR-93 was over-expressed in human T-cell leukemia virus 1-
transformed human T-cell lines and primary peripheral blood
mononuclear cells from adult T-cell leukemia patients [46].
miR-681 + ND
miR-205 + miR-205 expression was down-regulated in breast cancer, but up-
regulated in other types of cancer including lung cancer, bladder
cancer and ovarian cancer [63].
miR-142-3p + miR-142-3p was over-expressed in childhood B-cell precursor acute
lymphoblastic leukemia [64].
Note: miRNAs with p value < 0.01 and fold change >2.0 were considered significantly changed. The symbols +, ++, and +++; or -, - -, and - - - indicate that the
miRNA was up- or down-regulated at a magnitude of 2-4, 4-6, and >6 fold, respectively. No symbol is given if the miRNA was not significantly changed. ND
means not determined.
Figure 2 Number of the differentially expressed miRNAs (DEMs) in livers of mice treated with ENU at different post-treatment days.
The bars above and below x axis represent up- and down- regulated DEMs, respectively. The numbers at the top of each bar denote the
amount of DEMs represented by the bar.
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Page 5 of 14Figure 3 The temporal expression changes of three miR-34 family members and one miR-762 family member as determined by PCR
arrays and individual TaqMan assays. The data for each time point are the mean of 4 or 5 samples with its standard error. The asterisk
indicates there is a significant difference between the treatment and control at that time point (p < 0.01).
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Page 6 of 14Figure 4 Hierarchical clustering analysis of 43 deferentially expressed miRNAs. Fold change for each miRNA at each time point after ENU
treatment was determined relative to the vehicle-treated controls and logarithmically transformed (base 2). Hierarchical cluster analysis was
conducted using a Euclidean distance-calculating and Ward linking method. Up-regulated miRNAs are shown in red; down-regulated miRNAs in
green; and no-changes in black. Four clustering groups were identified and named as I, II, III, and IV, respectively.
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Page 7 of 14DEMs were input into IPA, and the related functions
and pathways were determined and are provided in
Figure 6 and Additional File 3. The most relevant biologi-
cal functions putatively controlled by the ENU-induced
DEMs are related to mutagenesis and tumorigenesis,
involved in tumor/cancer formation, cell cycle and DNA
repair, as well as other ENU-toxicity related functions.
Discussion
To explore the temporal response of miRNA to treat-
ment of genotoxic carcinogens, mice were administrated
with one dose of 120 mg/kg ENU, which can signifi-
cantly induce tumors and mutations in mouse liver [13].
The ENU treatment resulted in temporal changes in
miRNA expression in mouse liver and the altered
Figure 5 Average fold changes of the 4 clustering groups with the different sampling times. The fold changes of all miRNAs in one
clustering group were averaged and plotted with its standard errors of the mean against the time points after ENU treatment.
Figure 6 The top 10 biological functions altered by ENU treatment according to the p values. The target genes of the differentially
expressed miRNAs at post-treatment days 7 and 15 were computationally predicted by miRanda algorithm. The top 5% predicted genes were
utilized for functional analysis using Ingenuity Pathway Analysis system. The threshold (p = 0.05) indicates whether the functions are significantly
changed by the treatment or not. If a p value of a function is less than the threshold, the function is considered as significantly changed.
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and mutagenicity of ENU according to the in silico
functional analysis of the DEMs.
Temporal changes in miRNA expression after ENU
treatment
miRNA aberrant expression has been found to be a
common feature of tumor malignancy [21]. Several stu-
dies on carcinogen-altered miRNA expression have been
conducted and showed that chronic or subchronic carci-
nogen exposure can dysregulate miRNA expression.
Long-term exposure of female Fisher 344 (F344) rats to
a tamoxifen-containing diet led to alterations in the
miRNA expression profile in liver tissue prior to tumor
formation [22]. Sprague-Dawley rats treated with 2-AAF
for 12 or 24 weeks exhibited disrupted regulation of the
miR-34a-p53 feed-back loop and substantial deregula-
tion of expression of miR-18, miR-21, miR-182, and
miR-200 family miRNAs [11]. Male F344 rats continu-
ously fed with NNK for up to 20 weeks resulted in
alteration of miRNA expression in the lungs of rats [9].
Although these studies demonstrated that carcinogen
exposures were able to alter expression of certain miR-
NAs, such experiments could not provide information
on temporal response of miRNAs to carcinogen expo-
sure. The alteration of miRNA expression by these sub-
chronic to chronic treatments do not provide the
response period of miRNAs to treatment. The changes
could result from the cumulative effects of persistent
l o n g - t e r mc h e m i c a le x p o s u r eo rf r o mas h o r tt e r m
response. At present, the duration of miRNA response
to exposure to a genotoxic carcinogen in animals or
humans is unknown. In this study, mice received only a
single dose of a potent genotoxic carcinogen ENU and
were sacrificed at different time points so that temporal
response of miRNA expression to the treatment can be
determined. The results clearly demonstrate that expo-
sure of mice to a single dose of ENU can cause distinc-
tive alterations in miRNA expression at the different
sampling times after the ENU treatment (Table 1 and
Figures 1, 2, 3 and 4).
Sampling time after the ENU exposure appears to be a
very important parameter in miRNA expression in both
the amount of DEMs and their fold-change levels. Prin-
cipal component analysis indicates that mouse livers
sampled at 7 and 15 days after ENU treatment display
distinctive miRNA expression patterns compared to
controls and other sampling time points (Figure 1).
Three DEMs were found one day after the ENU treat-
ment. The number of DEMs increased with the sam-
pling time, reaching the peak at PTD 15 with 32 DEMs.
The amount of DEMs declined after 15 days and only 5
DEMs were identified at PTDs 30 and 120 (Figure 2).
The magnitude of the DEMs’ expression alteration was
also changed with time. Most of the DEMs had their
highest fold-changes at PTDs 7 or 15 (Figures 4 and 5).
Hierarchical clustering analysis of the DEMs divided
them into four groups according to the change direction
and intensity of these DEMs’ expression alteration. The
DEMs in Groups II and IV responded to the ENU expo-
sure quickly, indicating that some miRNAs can be chan-
ged by the treatment within a few days. However,
regarding the alteration of miRNA expression induced
by the ENU treatment, both the amount and the change
magnitude of the DEMs peaked at PTD 15.
The pattern of temporal changes in miRNA expres-
sion after ENU treatment is different from previous
reports on gene expression changed by ENU treatment
[17]. In the previous studies, gene expression changes in
both amount and intensity peaked at 4 hours and
declined at 20 hours, 14 and 28 days after administra-
tion of ENU. The mechanism(s) for the difference
between the temporal changes induced by ENU in
miRNA expression and gene expression is unknown. It
is possible that many genes, such as DNA repair genes,
can directly respond to the DNA damage caused by
ENU exposure whereas miRNAs as posttranscriptional
regulators for gene expression may respond indirectly to
ENU insults via the alteration of gene expression [23].
Also, turnover rates for mature mRNAs and miRNAs
could play a role in the difference. Mature miRNAs gen-
erally have lower turnover rates and exist longer than
mRNAs [24].
The pattern of the temporal expression change could
result from biological responses of liver miRNAs to the
genotoxic and cytotoxic effects of ENU. miRNA expres-
sion may vary between different biological mechanisms
like DNA adduct formation by ENU, cell death induced
by the DNA damage, and cell proliferation due to the
cell death. The DNA damage induced by ENU is very
fast, occurring within hours after treatment [25]. How-
ever, the DNA repair and cell proliferation processes
c o u l dt a k eaf e ww e e k s[ 2 6 ] .S o m em i R N A sl i k em i R -
34a could respond to the DNA damage quickly and
exhibited dysregulation within one day while most miR-
NAs that function mainly as regulators for cell differen-
tiation and proliferation altered their expression only
after several days.
In silico pathway analysis of the functions of the ENU-
induced DEMs
ENU, as a potent monofunctional ethylating agent,
reacts directly with the nucleophilic nitrogen and oxy-
gen atoms in DNA and with the oxygen atoms in the
backbone phosphates, forming various ethylated pro-
ducts including N
7-ethylgunine, N
3-ethyladenine, O
6-
ethylguanine, O
2-a n dO
4-ethylthymine, and O
2-ethylcy-
tosine [16,25]. Once formed in the DNA, these products
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Page 9 of 14can result in cell death, like apoptosis [27] or become
the substrate of cellular repair processes of various
kinds, such as specific dealkylation by the O
6-a l k y l g u a -
nine-DNA-alkyltransferase (AGT) [28], removal of N
7-
alkylguanine or N
3-alkylguanine by specific glycosylases
[29], or removal O
4-alkylthymine by the more general
action of the nucleotide excision repair system [30].
Also, ENU is known to induce cell proliferation [31]. If
miRNAs are involved in the regulation of the genes that
are related to genotoxic functions like cell proliferation,
cell cycle arrest, apoptosis, and DNA repair, expression
of miRNAs related to these functions should be changed
by the ENU treatment. Indeed, our literature search
results indicate that most of the DEMs induced by ENU
treatment function as regulators for cell cycle arrest
[32], cell proliferation [33], apoptosis [34], DNA repair
[35] and other biological processes related to ENU cyto-
toxicity, genotoxicity and carcinogenicity (Table 1).
Because each miRNA can regulate many target genes
and several miRNAs may affect a single gene, it is
important to analyze the functions of all DEMs together.
Computational approaches have been a major focus in
determining the general principles that are thought to
govern miRNA target recognition and mode of action.
In this study, the target genes computationally predicted
by the miRanda algorithm were used for functional ana-
lysis. The miRanda algorithm was developed by the San-
ger Institute and is widely used in miRNA studies [36].
The top 5% target genes of all of the DEMs were
selected and used for IPA functional analysis. The top
functions affected by the ENU exposure are tumor mor-
phology, cell cycle, DNA replication, recombination and
repair, and cancer. These biological functions identified
by the analysis show that the DEMs are related to ENU-
induced carcinogenesis (Figure 6). For example, many
genes involved in DNA repair or response to DNA
damage can be dysregulated by ENU treatment [37] and
the miRNAs that target these genes could change their
expression to regulate these functional processes.
MiR-34 family might have the potential to be explored as
a biomarker for genotoxin exposure
Our results indicate that some miRNAs responded to
ENU treatment with a wide temporal range. These miR-
NAs might have the potential to be used as biomarkers
for predicting the genotoxic carcinogenicity of chemi-
cals. Among these miRNAs, the miR-34 family is worth
special attention. All of the 3 miRNAs were significantly
changed at four different time points (Figure 3). Their
expressions were enhanced by 3.21-fold (miR-34a), 3.11-
fold (miR-34b) and 2.37-fold (miR-34c) on PTD 1 and
the fold changes continued to increase and peaked at
PTDs 7 or 15. The miR34 family genes are the direct
transcription targets of tumor suppressor p53 [32,38].
miR-34b and miR-34c are encoded by the same primary
transcript from chromosome 11 in human or chromo-
some 9 in mouse while miR-34a is located in a different
chromosome [35]. The promoter region of miR-34a and
miR-34b/c each contain a palindromic sequence that
matches the canonical p53 binding site and can be
bound by p53 as shown by chromatin immunoprecipita-
tion [32]. Interestingly, our results found that miR-34b
and miR-34c changed in correlated manner at all the
sampling time points (Figure 3). miRNAs in miR-34
family play important roles in various p53-initiated bio-
logical processes. Up-regulation of miR-34a and miR-
34b/c caused a cell-cycle arrest in the G1 phase [32].
miR-34b/c inhibits cell proliferation and colony forma-
tion in soft agar [39]. Introduction of miR-34a and miR-
34b/c into primary human diploid fibroblasts induces
cellular senescence [35]. Re-expression of miR-34a in
tumor cells induced apoptosis [38]. These biological
processes controlled by miRNAs in the miR-34 family
are related to ENU cytotoxicity, genotoxicity, and carci-
nogenicity. Our results indicate that the miR-34 family
of miRNAs seems to have the potential to be valuable
biomarkers for toxicological application.
Conclusions
Our study indicates that one dose treatment of ENU, a
chemical inducing tumors and mutations, resulted in
deregulation of a large number of miRNAs. In silico
functional analysis suggested that these miRNAs were
related to ENU mutagenesis and carcinogenesis in the
mouse liver. The deregulation of ENU-induced miRNA
expression changed with time and peaked at day 15
after the treatment. The findings suggest that one to
t w ow e e k sa f t e rE N Ue x p o s u r ei st h eb e s tt i m ef o r
miRNA expression sampling. Moreover, miRNAs in the
miR-34 family worth further study to explore their
potential as biomarkers for exposure of genotoxic
carcinogens.
Methods
Animal treatment
The animal treatment protocol and mutant frequency
analysis was described previously [13]. Briefly, six-
month-old female Big Blue mice were injected intraperi-
toneally with a single dose of 120 mg/kg body weight
ENU (CAS# 759-73-9, Sigma, St. Louis, MO) or the
vehicle dimethylsulfoxide (DMSO, Sigma) in 1 ml/kg
b o d yw e i g h t( 0 . 1 % ) .F o rE N Ut r e a t m e n t ,g r o u p so f4o r
5 animals were sacrificed on PTDs 1, 3, 7, 15, 30, and
120. For the vehicle treatment, 4 and 3 animals were
sacrificed on PTDs 1 and 30, respectively. DMSO is not
carcinogenic and mutagenic [40]. It has showed no
effects on gene expression in the dose that we used [41].
Also, our previous study demonstrated that DMSO did
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sampling times [13]. Therefore, the 7 control samples
were grouped together as a common control group for
the treatment groups sampling at the different time
points to increase the statistical power. The tissues were
isolated and frozen at -80°C. The liver samples were
used for this study. All animal experiments were con-
ducted by following the recommendations set forth by
our Institutional Animal Care and Use Committee.
miRNA isolation
About 60 mg of liver tissue was cut from each frozen liver
sample and suspended in RNAlater-ICE (Ambion Inc.,
Austin, TX). The tissue pieces were transferred to 600 μl
RNA lysis/binding buffer and minced using Tissue Tearor™
(BioSpec Products Inc., Bartlesville, OK). miRNAs were
isolated using mirVana™ miRNA isolation kit (Ambion)
that specifically captures small RNAs with length of less
than 200 nucleotides. The isolated RNAs were resolved in
100 μl nuclease-free water (Ambion). RNA concentrations
were determined using NanoDrop 1000 Spectrophot-
ometer (NanoDrop Technologies, Wilmington, Delaware).
The quality of RNA samples was characterized on an Agi-
lent BioAnalyzer (Agilent Technologies, Santa Clara, CA)
using an RNA6000 Nano Chip (Agilent).
PCR Array analysis of miRNA expression
Two hundred nanograms of enriched small RNA were
converted into cDNA using RT
2 miRNA First Strand
Kit (SABiosciences Corporation, Frederick, MD). The
cDNAs were mixed with 2 × RT
2 SYBR Green PCR
Master Mix (SABiosciences) and dispersed into 384-well
M o u s eG e n o m em i R N AP C RA r r a y( M A M - 3 1 0 0 E ,
SABiosciences) with 10 μl/well reaction volume. The
PCR array contained a panel of primer sets for 376
mouse miRNAs, four small RNAs as the internal con-
trols and four quality controls. The real-time qRT-PCR
was performed on a 7900 real-time PCR system
(Applied Biosystems Inc., Foster, CA) with following
cycling parameters: 95°C for 10 mins, then 40 cycles of
95°C for 15 s, 60°C for 30 s and 72°C for 30 s. SYBR
Green fluorescence was recorded from every well during
the annealing step of each cycle. The threshold cycle
(Ct) value of each sample was calculated with software
SDS 2.3 (Applied Biosystems). To calculate Cts, we set
the threshold line as 0.15 and kept it the same across all
of the analyses. The baseline was automatically defined
by the software.
Normalization and statistical analysis
Normalization and statistical analysis of miRNA expres-
sion were conducted using SABiosciences Online PCR
Array Data Analysis Web Portal. MiRNA expressions
were compared between the treatment group at each
time point and the control group. The ΔΔCt method
was utilized to calculate the fold change (FC). Four
genes, snoRNA251, snoRNA202, snoRNA142, and U6 in
the PCR arrays, were averaged as the endogenous con-
trol and the vehicle control group was used as external
control to normalize each sample. The formula: FC = 2^
[-(mean of ΔCt values of treated samples - mean of ΔCt
values of control samples)] was used for up-regulated
gene, while FC = - 2^ (mean of ΔCt values of treated
samples - mean of ΔCt values of control samples) was
used for the down-regulations. T-tests were used to cal-
culate the p value to determine whether there is a signif-
icant difference for miRNAe x p r e s s i o nb e t w e e nt h e
control and the treatment groups for each miRNA at
each time point. miRNAs with p < 0.01 and the absolute
value of FC >2.0 were considered as DEMs.
Principal component analysis and hierarchical clustering
analysis
Principal component analysis of expression profiles of all
miRNAs from each time point after the ENU treatment
was conducted using the autoscaled method within
ArrayTrack [42]. The normalized ΔCt values were used
for this analysis and the analysis was performed without
filtering any miRNAs.
To examine types of expression changes, hierarchical
clustering analysis was performed using R software
http://www.r-project.org/. The miRNAs whose expres-
sions were significantly differentially expressed at least
at one sampling time were used for the clustering. The
FCs for control samples were set to zero. Euclidean and
Wards methods were used for distance-calculation and
linkage, respectively.
In silico Functional analysis of the DEMs
The miRanda database was used for identification of
DEMs’ target genes http://microrna.sanger.ac.uk/
sequences/. The top 5% of the most reliable predicted
target genes of the DEMs at PTDs 7 and 15 were
selected according to the p values given in the database.
A total of 1376 genes were determined as the predictive
target genes of these DEMs. The selected target genes
were then input into Ingenuity Pathway Analysis (IPA)
software (Ingenuity Systems, Inc., Redwood City, CA).
Ingenuity Core Analysis and Knowledge Base was used
as the reference set. IPA interpreted the genes in the
context of biological processes, pathways and molecular
networks and defined the most relevant biological func-
tions of the predicted genes of the DEMs.
TaqMan qPCR confirmation of the temporal expression
changes of miR-34 family miRNAs
TaqMan MicroRNA Assays were used to confirm the
temporal expression changes of 3 miR-34 family
Li et al. BMC Genomics 2010, 11:609
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Page 11 of 14members, mmu-miR-34a, mmu-miR-34b-5p, and mmu-
miR-34c, as well as a miR-762 family member, mmu-
miR-762. The experiment also severed as the verification
of the RT
2-mouse miRNA PCR array assay. The TaqMan
miRNA assay kits were purchased from Applied Biosys-
tems (Foster City, CA). The same small RNA samples
used for the PCR arrays were also used for the TaqMan
miRNA assays. The experiment was performed by follow-
ing the manufacturer’s protocol. In brief, each 10 μl
reverse transcription (RT) reaction contained 44 ng of
small RNA, 50 nM stem-loop RT primer, 1 × RT buffer,
0.25 mM each of dNTPs, 3.33 U/μlM u l t i S c r i b e ™ reverse
transcriptase and 0.25 U/μlR N a s ei n h i b i t o r .T h eR T
reactions were incubated in a GeneAmp PCR System
9700 (Applied Biosystems) for 30 min at 16°C, 30 min at
42°C, followed by 5 min at 85°C, and then held at 4°C.
Each real-time PCR reaction (10 μl volume) containing
0.78 μl of RT product, 5 μl of 2× TaqMan Universal PCR
Master Mix, and 0.5 μlT a q M a nM i c r o R N Aa s s a y( t h e
mixture of TaqMan probe, forward primer, and reverse
primer). The PCR reaction was conducted in an Applied
Biosystems 7500 Fast Real-Time PCR System at 95°C for
10 min, followed by 40 cycles of 95°C for 15 sec and 60°C
for 1 min. The threshold cycle (Ct) is defined as the frac-
tional cycle number at which the fluorescence exceeds
the fixed threshold of 0.02. Four samples at each time
point were used for the TaqMan confirmation.
Accession numbers
All PCR array Ct raw data are available through Gene
Expression Omnibus (Series accession numbers:
GSE20248).
Additional material
Additional file 1: The normalized Ct values (dCt) for the control
samples and treatment samples at different days after ENU
treatment.
Additional file 2: The p values and fold changes of microRNAs at
different days after ENU treatment.
Additional file 3: The biological functions related to the top 5%
targets of DEMs.
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